Tse Pui Shan. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2003. / Includes bibliographical references (leaves [191]-216). / Abstracts in English and Chinese. / ACKNOWLEDGEMENTS --- p.I / ABBREVIATIONS --- p.III / ABSTRACT --- p.VIII / 摘要 --- p.X / PUBLICATIONS --- p.XII / TABLE OF CONTENTS --- p.XIII / Chapter CHAPTER 1: --- GENERAL INTRODUCTION / Chapter 1.1 --- Human Immune System and Cancer --- p.1 / Chapter 1.1.1 --- Brief Introduction of the Human Immune System --- p.1 / Chapter 1.1.2 --- Prevalence of Cancer in Hong Kong --- p.4 / Chapter 1.1.3 --- The Role of the Immune System in Tumorigenesis --- p.4 / Chapter 1.1.4 --- Cancer Treatment --- p.5 / Chapter 1.1.5 --- Cancer Prevention --- p.5 / Chapter 1.2 --- Mushroom Polysaccharides --- p.6 / Chapter 1.2.1 --- General Aspects of Mushroom Polysaccharides --- p.6 / Chapter 1.2.2 --- Structure of Mushroom Polysaccharides --- p.9 / Chapter 1.2.2.1 --- Beta (P)-D-glucans --- p.9 / Chapter 1.2.2.2 --- Heteroglucans and Protein-bound Polysaccharides --- p.10 / Chapter 1.2.2.3 --- Structure-Function Interactions of Polysaccharides --- p.12 / Chapter 1.2.3 --- Molecular Interactions of Polysaccharides --- p.14 / Chapter 1.2.4 --- Biological Activities of Polysaccharides --- p.15 / Chapter 1.2.4.1 --- Anti-tumor Activities of Polysaccharides --- p.15 / Chapter 1.2.4.2 --- Immunomodulatory Activities of Polysaccharides --- p.16 / Chapter 1.3 --- Yun Zhi (Coriolus versicolor) --- p.17 / Chapter 1.3.1 --- General Features of Yun Zhi --- p.17 / Chapter 1.3.2 --- Traditional Uses of Yun Zhi --- p.20 / Chapter 1.3.3 --- Active Ingredients of Yun Zhi --- p.20 / Chapter 1.3.3.1 --- "Origin, Properties and Composition of PSK" --- p.21 / Chapter 1.3.3.2 --- "Origin, Properties and Composition of PSP" --- p.22 / Chapter 1.3.4 --- Pharmacological Actions of PSP and PSK --- p.25 / Chapter 1.3.4.1 --- Immunomodulatory Activities --- p.25 / Chapter 1.3.4.2 --- Anti-tumor Activities --- p.32 / Chapter 1.3.4.2 --- Antiviral and Antimicrobial Activities --- p.35 / Chapter 1.3.4.3 --- Antioxidant Activities --- p.36 / Chapter 1.3.5 --- Human Clinical Studies on Yun Zhi --- p.36 / Chapter 1.3.6 --- Toxicology of Yun Zhi --- p.42 / Chapter 1.4 --- Danshen (Salvia miltiorrhiza) --- p.43 / Chapter 1.4.1 --- General Features of Danshen --- p.43 / Chapter 1.4.2 --- Traditional Uses of Danshen --- p.46 / Chapter 1.4.3 --- Active Ingredients of Danshen --- p.47 / Chapter 1.4.4 --- Pharmacological Actions of Danshen --- p.50 / Chapter 1.4.4.1 --- Cardiovascular Effects --- p.50 / Chapter 1.4.4.2 --- Scavenging Effects on Free Radicals --- p.52 / Chapter 1.4.4.3 --- Hepatoprotective Effects --- p.54 / Chapter 1.4.4.4 --- Anti-tumor Effects --- p.56 / Chapter 1.4.4.5 --- Renal Protective Effects --- p.56 / Chapter 1.4.5 --- Human Clinical Studies --- p.57 / Chapter 1.4.6 --- Toxicity of Danshen --- p.59 / Chapter 1.5 --- Aims and Scopes of This Investigation --- p.60 / Chapter CHAPTER 2: --- MATERIALS AND METHODS / Chapter 2.1 --- Normal Subjects --- p.62 / Chapter 2.1.1 --- Inclusion and Exclusion Criteria of Recruitment --- p.62 / Chapter 2.1.2 --- Study Design and Procedure --- p.63 / Chapter 2.1.3 --- Treatment and Blinding --- p.65 / Chapter 2.1.4 --- Blood Sampling --- p.66 / Chapter 2.1.5 --- Blood Processing for Assessment of Immunological Functions --- p.67 / Chapter 2.2 --- Materials --- p.69 / Chapter 2.2.1 --- Endotoxin Assay --- p.69 / Chapter 2.2.2 --- Reagents for Whole Blood Assay --- p.69 / Chapter 2.2.2.1 --- Plain RPMI 1640 Medium --- p.69 / Chapter 2.2.2.2 --- Phosphate-Buffered Saline (PBS) --- p.69 / Chapter 2.2.2.3 --- Mitogens --- p.70 / Chapter 2.2.3 --- Reagents for Total RNA Extraction --- p.70 / Chapter 2.2.3.1 --- Ficoll-Paque Density Gradient Solution --- p.70 / Chapter 2.2.3.2 --- RNA Extraction Kit --- p.70 / Chapter 2.2.3.3 --- RNase-Free DNase Set --- p.71 / Chapter 2.2.3.4 --- β-Mercaptoethanol (β-ME) Solution --- p.71 / Chapter 2.2.4 --- Reagents for Flow Cytometric Analysis of T/B/NK Cell Ratios --- p.71 / Chapter 2.2.4.1 --- MultiTEST IMK Kit with TruCOUNT Tubes --- p.71 / Chapter 2.2.4.2 --- FACSFlo´wёØ Sheath Fluid --- p.74 / Chapter 2.2.4.3 --- CaliBRITE 3 and APC Beads --- p.74 / Chapter 2.2.5 --- Immunoassay Kits for Measuring Cytokines Level --- p.75 / Chapter 2.2.5.1 --- Enzyme-linked Immunosorbent Assay (ELISA) Kits of Cytokines --- p.75 / Chapter 2.2.5.2 --- Human Thl/Th2 Cytokine Cytometric Bead Array (CBA) Kit-II --- p.75 / Chapter 2.2.6 --- Reagents and Buffers for Gel Electrophoresis --- p.78 / Chapter 2.2.6.1 --- Ethidium Bromide (EtBr) --- p.78 / Chapter 2.2.6.2 --- Gel Loading Solution (5X) --- p.78 / Chapter 2.2.6.3 --- Tris-Acetate-EDTA (TAE) Buffer --- p.78 / Chapter 2.2.6.4 --- Agarose Gel --- p.78 / Chapter 2.2.6.5 --- 100 base pair DNA Ladder --- p.79 / Chapter 2.2.7 --- Kits and Reagents for Messenger RNA (mRNA) Expression Array --- p.79 / Chapter 2.2.7.1 --- Human Inflammatory Cytokine/Receptor GEArraýёØ Q Series Kit --- p.79 / Chapter 2.2.7.2 --- Deoxynucleoside Triphosphates (dNTPs) --- p.84 / Chapter 2.2.7.3 --- Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLVRT) --- p.84 / Chapter 2.2.7.4 --- Rnasin Ribonuclease Inhibitor --- p.84 / Chapter 2.2.7.5 --- Biotin-16-2'-deoxy-uridine-5'-triphosphate (Biotin-16-dUTP) --- p.85 / Chapter 2.2.7.6 --- Salmon Sperm DNA Solution --- p.85 / Chapter 2.2.7.7 --- 100 % Sodium Dodecyl Sulfate (SDS) Solution --- p.86 / Chapter 2.2.7.8 --- 20X SSC --- p.86 / Chapter 2.2.7.9 --- ECL Films (Hyperfilm 226}0ёØ ECL 226}0ёØ) --- p.86 / Chapter 2.3 --- Methods / Chapter 2.3.1 --- Endotoxin Assay --- p.87 / Chapter 2.3.2 --- Whole Blood Assay (WBA) --- p.88 / Chapter 2.3.3 --- Isolation and Preparation of Plasma and Peripheral Blood Mononuclear Cells (PBMC) from EDTA Blood --- p.88 / Chapter 2.3.4 --- Total RNA extraction --- p.89 / Chapter 2.3.5 --- Flow Cytometric Analysis of T/B/NK Cell Ratios --- p.90 / Chapter 2.3.6 --- Immunoassays of Plasma Samples or Culture Supernatant in WBA --- p.92 / Chapter 2.3.6.1 --- Enzyme-linked Immunosorbent Assay (ELISA) --- p.92 / Chapter 2.3.6.2 --- Human Thl/Th2 Cytokine Cytometric Bead Assay (CBA) --- p.93 / Chapter 2.3.7 --- mRNA Expression Study --- p.94 / Chapter 2.3.7.1 --- Agarose Gel Electrophoresis --- p.94 / Chapter 2.3.7.2 --- cDNA Expression Array Analysis --- p.95 / Chapter 2.3.8 --- Statistical Analysis --- p.96 / Chapter CHAPTER 3: --- ENDOTOXIN LEVEL OF YUN ZHI-DANSHEN CAPSULES & SAFETY MEASURES ON STUDY POPULATION IN THE CLINICAL TRIAL / Chapter 3.1 --- Introduction --- p.98 / Chapter 3.2 --- Results --- p.101 / Chapter 3.2.1 --- Endotoxin Level of the Yun Zhi and Danshen Active Capsule --- p.101 / Chapter 3.2.2 --- Study Population --- p.103 / Chapter 3.2.3 --- Dropout Cases --- p.103 / Chapter 3.2.4 --- Safety Parameters --- p.104 / Chapter 3.2.5 --- Compliance Rates --- p.104 / Chapter 3.3 --- Discussion --- p.109 / Chapter CHAPTER 4: --- FLOW CYTOMETRIC ANALYSIS OF T/B/NK CELL RATIOS OF HEALTHY SUBJECTS TAKING YUN ZHI-DANSHEN CAPSULES / Chapter 4.1 --- Introduction --- p.112 / Chapter 4.2 --- Results --- p.118 / Chapter 4.2.1 --- The Percentage and Absolute Count of T Lymphocytes (CD3+) --- p.118 / Chapter 4.2.2 --- The Percentage and Absolute Count of T Helper (TH) Lymphocytes (CD3+ CD4+) --- p.121 / Chapter 4.2.3 --- The Percentage and Absolute Count of Cytotoxic T (CTL) and T Suppressor (Ts) Lymphocytes (CD3+ CD8+) --- p.124 / Chapter 4.2.4 --- The Ratio of T Helper Lymphocytes (CD3+ CD4+) and Cytotoxic T (CTL) and T Suppressor (Ts) Lymphocyes (CD3+ CD8+) --- p.127 / Chapter 4.2.5 --- The Percentage and Absolute Count of B Lymphocytes (CD19+) --- p.129 / Chapter 4.2.6 --- The Percentage and Absolute Count of NK Lymphocytes (CD3- CD 16+ and/or CD56+) --- p.132 / Chapter 4.2.7 --- The Absolute Count of Lymphocytes (CD45+) --- p.135 / Chapter 4.3 --- Discussion --- p.138 / Chapter CHAPTER 5: --- PLASMA CONCENTRATION OF SOLUBLE CYTOKINE RECEPTOR AND EX VIVO CYTOKINE PRODUCTION OF HEALTHY SUBJECTS TAKING YUN ZHI-DANSHEN CAPSULES / Chapter 5.1 --- Introduction --- p.142 / Chapter 5.2 --- Results --- p.147 / Chapter 5.2.1 --- Plasma Concentration of Soluble IL-2 Receptor --- p.147 / Chapter 5.2.2 --- Ex vivo Cytokine Production --- p.147 / Chapter 5.2.3 --- Mitogen Induced IL-6 Production --- p.150 / Chapter 5.2.4 --- Mitogen Induced IFN- γ Production --- p.150 / Chapter 5.2.5 --- Mitogen Induced TNF- a Production --- p.153 / Chapter 5.2.6 --- Mitogen Induced IL-10 Production --- p.153 / Chapter 5.3 --- Discussion --- p.156 / Chapter CHAPTER 6: --- "GENE EXPRESSION OF CYTOKINES, CHEMOKINES AND RECEPTORS OF PBMC OF HEALTHY SUBJECTS TAKING YUN ZHI- DANSHEN CAPSULES" / Chapter 6.1 --- Introduction --- p.162 / Chapter 6.2 --- Results --- p.165 / Chapter 6.2.1 --- Gene Expression of IL-2 Receptor β chain --- p.165 / Chapter 6.2.2 --- Gene Expression of IL-2 Receptor γ chain --- p.165 / Chapter 6.2.3 --- Gene Expression of IL-6 Receptor --- p.166 / Chapter 6.2.4 --- "Gene Expression of Other Cytokines, Chemokines and Receptors" --- p.169 / Chapter 6.3 --- Discussion --- p.172 / Chapter CHAPTER 7: --- CONCLUDING REMARKS AND FUTURE / PERSPECTIVES --- p.176 / APPENDICES --- p.184 / REFERENCES --- p.192

Ng Chau Wah Stephen. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2003. / Includes bibliographical references (leaves 120-135). / Abstracts in English and Chinese. / Abstract --- p.i / Acknowledgements --- p.viii / Publications --- p.ix / Abbreviations --- p.x / Chapter Chapter 1 --- Introduction / Chapter 1.1 --- Traditional Chinese Medicine --- p.1 / Chapter 1.2 --- Danshen --- p.7 / Chapter 1.2.1 --- Chemical constituents of Danshen --- p.7 / Chapter 1.2.2 --- Pharmacology of Danshen --- p.10 / Chapter 1.3 --- Vascular system --- p.13 / Chapter 1.3.1 --- Physiology of blood vessels --- p.13 / Chapter 1.3.2 --- Vascular smooth muscle contraction --- p.14 / Chapter 1.3.3 --- Mechanism of vascular smooth muscle contraction --- p.15 / Chapter 1.3.3.1 --- Adrenoceptor in vascular system --- p.19 / Chapter 1.3.3.2 --- Muscarinic receptor in vascular system --- p.20 / Chapter 1.3.3.3 --- Synthesis and release of Nitric Oxide (NO)in vascular system --- p.22 / Chapter 1.3.3.4 --- Synthesis and release of postanoidsin vascular system --- p.25 / Chapter 1.3.3.5 --- Synthesis and release of histaminein vascular system --- p.28 / Chapter 1.3.3.6 --- Synthesis and release of Calcitonin gene-related peptide in vascular system --- p.29 / Chapter 1.4 --- Aims of the studies --- p.33 / Chapter Chapter 2 --- Materials and methods / Chapter 2.1 --- Materials --- p.35 / Chapter 2.2 --- Methods - General procedures --- p.35 / Chapter 2.2.1 --- Preparations of drug solutions --- p.35 / Chapter 2.2.2 --- Animals used and anaesthetization --- p.36 / Chapter 2.2.3 --- Cannulation of carotid artery and jugular vein --- p.37 / Chapter 2.2.4 --- Blood pressure measurement --- p.37 / Chapter 2.2.5 --- Knee joint denervation --- p.38 / Chapter 2.2.6 --- Knee joint blood flow measurement --- p.39 / Chapter 2.3 --- Methods - Specific procedures --- p.41 / Chapter 2.3.1 --- Validation of Laser Doppler Imaging (LDI) measurements --- p.41 / Chapter 2.3.2 --- Actions of topical administration of Danshen --- p.42 / Chapter 2.3.2.1 --- Studies of the mechanism(s) of action of Danshen --- p.43 / Chapter 2.3.2.2 --- Investigation for α-adrenoceptor antagonist activity --- p.44 / Chapter 2.3.2.3 --- Investigation for neural involvement --- p.44 / Chapter 2.3.3 --- Actions of intravenous administration of Danshen --- p.45 / Chapter 2.3.4 --- Data analysis --- p.45 / Chapter Chapter 3 --- Results / Chapter 3.1 --- Validation of LDI measurement --- p.47 / Chapter 3.2 --- Actions of intravenous administration of Danshen --- p.53 / Chapter 3.3 --- Actions of topical administration of Danshen --- p.53 / Chapter 3.4 --- Muscarinic receptor antagonist on Danshen --- p.61 / Chapter 3.5 --- β-adrenoceptor antagonist on Danshen --- p.67 / Chapter 3.6 --- Danshen on α-adrenoceptor agonist-induced vasoconstriction --- p.74 / Chapter 3.7 --- Nitric oxide synthase inhibitor on Danshen --- p.79 / Chapter 3.8 --- Cyclo-oxygenase (COX) inhibitor on Danshen --- p.83 / Chapter 3.9 --- Histamine receptor antagonists on Danshen --- p.87 / Chapter 3.10 --- CGRP receptor antagonist on Danshen --- p.92 / Chapter 3.11 --- Effect of denervation on Danshen --- p.92 / Chapter Chapter 4 --- Discussion --- p.100 / Reference --- p.120

Yim Wan Sze. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (leaves 95-109). / Abstracts in English and Chinese. / Acknowledgements --- p.i / Abstract --- p.ii / 槪論 --- p.iv / Table of contents --- p.v / List of abbreviations --- p.xii / List of Figures --- p.xv / List of Tables --- p.xviii / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Oxidation stress --- p.1 / Chapter 1.1.1 --- Free radicals --- p.2 / Chapter 1.1.1.1 --- Hydrogen peroxide --- p.3 / Chapter 1.1.1.2 --- Menadione --- p.4 / Chapter 1.1.2 --- Diseases related to oxidative stress --- p.5 / Chapter 1.1.3 --- Liver Injury --- p.5 / Chapter 1.1.4 --- Antioxidants --- p.7 / Chapter 1.1.4.1 --- Importance of antioxidant --- p.7 / Chapter 1.1.4.2 --- Examples of antioxidant --- p.7 / Chapter 1.2 --- Traditional Chinese Medicinal (TCM) formula Wu-zi-yan-zong-wan (WZ) --- p.8 / Chapter 1.2.1 --- The WZ medicinal formula --- p.8 / Chapter 1.2.2 --- Pharmacological actions of WZ --- p.9 / Chapter 1.2.3 --- Pharmacological actions of individual herbs --- p.10 / Chapter 1.2.3.1 --- Fructus Lycii --- p.10 / Chapter 1.2.3.2 --- Semen Cuscuta --- p.11 / Chapter 1.2.3.3 --- Fructus Rubi --- p.12 / Chapter 1.2.3.4 --- Semen Plantaginis --- p.12 / Chapter 1.2.3.5 --- Fructus Schisandrae --- p.13 / Chapter 1.3 --- The relationship between the liver and kidney --- p.14 / Chapter 1.4 --- Objectives of study --- p.15 / Chapter Chapter 2 --- Preparation of Aqueous Extraction of Wu-zi-yan-zong-wan --- p.17 / Chapter 2.1 --- Introduction --- p.17 / Chapter 2.2 --- Materials and Methods --- p.18 / Chapter 2.2.1 --- Preparation of Wu-zi-yan-zong-wan (WZ) --- p.18 / Chapter 2.2.1.1 --- WZ extracts from raw materials (WZ-e) --- p.18 / Chapter 2.2.1.2 --- WZ extracts from commercial available ready-to-use powders (WZ-p) --- p.20 / Chapter 2.3 --- Results --- p.22 / Chapter 2.3.1 --- Extraction Yield for WZ-e --- p.22 / Chapter Chapter 3 --- In vitro Total Antioxidant Capacity of Aqueous Extracts of Wu-zi-yan-zong-wan and its Components --- p.24 / Chapter 3.1 --- Introduction --- p.24 / Chapter 3.1.1 --- Total Antioxidants: Trolox Equavalent Antioxidant Capacity (TEAC) --- p.24 / Chapter 3.1.2 --- Objectives --- p.25 / Chapter 3.2 --- Materials and methods --- p.26 / Chapter 3.2.1 --- Materials --- p.26 / Chapter 3.2.1.1 --- Reagents --- p.26 / Chapter 3.2.1.2 --- Instruments --- p.26 / Chapter 3.2.2 --- Methods --- p.26 / Chapter 3.2.2.1 --- Total Antioxidnats: Trolox Equavalent Antioxidnat Capacity (TEAC) --- p.26 / Chapter 3.2.3 --- Statistical analysis --- p.27 / Chapter 3.3 --- Results --- p.28 / Chapter 3.3.1 --- Antioxidnat Capacity of Trolox --- p.28 / Chapter 3.3.2 --- Antioxidant capacity of WZ-e formula --- p.28 / Chapter 3.3.3 --- Antioxidant capacity of WZ-p formula --- p.28 / Chapter 3.3.4 --- The total antioxidant capacity of WZ-e and its simplified formulae --- p.32 / Chapter 3.3.5 --- The total antioxidant capacity of WZ-p and its simplified formulae --- p.32 / Chapter 3.3.6 --- Synergetic effect of WZ-e and its simplified formulae --- p.34 / Chapter 3.3.7 --- Orthogonal analysis of WZ-e and its simplified formulae on TEAC assay --- p.40 / Chapter 3.4 --- Discussion --- p.42 / Chapter Chapter 4 --- Antioxidant Activity of Aqueous Extracts of Simplified Formulae of Wu-zi-yan-zong-wan in vitro --- p.44 / Chapter 4.1 --- Introduction --- p.44 / Chapter 4.1.1 --- In vitro antioxidant --- p.44 / Chapter 4.1.2 --- Antioxidant effect of Catechins --- p.44 / Chapter 4.1.3 --- MTT assay --- p.45 / Chapter 4.1.4 --- Objectives --- p.46 / Chapter 4.2 --- Materials and methods --- p.47 / Chapter 4.2.1 --- Materials --- p.47 / Chapter 4.2.1.1 --- Cell Culture --- p.47 / Chapter 4.2.1.2 --- Reagents --- p.47 / Chapter 4.2.2 --- Methods --- p.47 / Chapter 4.2.2.1 --- Cell Culture --- p.47 / Chapter 4.2.2.2 --- MTT Cytotoxicity Assay --- p.48 / Chapter 4.2.3 --- Statistical analysis --- p.48 / Chapter 4.3 --- Results --- p.49 / Chapter 4.3.1 --- The effect of WZ-e formula on HepG2 cells --- p.49 / Chapter 4.3.2 --- The effect of hydrogen peroxide on HepG2 cells --- p.49 / Chapter 4.3.3 --- The effect of menadione on HepG2 cells --- p.52 / Chapter 4.3.4 --- The effect of catechin on HepG2 cells --- p.52 / Chapter 4.3.5 --- The effect of WZ-e and its simplified formulae against hydrogen peroxide-induced cytotoxicty on HepG2 cells --- p.55 / Chapter 4.3.6 --- The effect of WZ-e and its simplified formulae against menadione-induced cytotoxicity on HepG2 cells --- p.60 / Chapter 4.3.7 --- The effect of WZ-p on HepG2 cells --- p.65 / Chapter 4.3.8 --- The effect of WZ-p and its simplified formulae against hydrogen peroxide-induced cytotoxicity on HepG2 cells --- p.67 / Chapter 4.3.9 --- The effect of WZ-p and its simplified formulae against menadione-induced cytotoxicity on HepG2 cells --- p.72 / Chapter 4.4 --- Discussion --- p.77 / Chapter Chapter 5 --- Effect of Aqueous Extract of Wu-zi-yan-zong-wan on Menadione-induced Oxidative Damage in Mouse Liver --- p.79 / Chapter 5.1 --- Introduction --- p.79 / Chapter 5.2 --- Materials and methods --- p.81 / Chapter 5.2.1 --- Materials --- p.81 / Chapter 5.2.1.1 --- Animals --- p.81 / Chapter 5.2.1.2 --- Reagents --- p.81 / Chapter 5.2.1.3 --- Apparatus --- p.81 / Chapter 5.2.2 --- Methods --- p.82 / Chapter 5.2.2.1 --- Animal treatments --- p.82 / Chapter 5.2.2.2 --- Collection of samples --- p.82 / Chapter 5.2.2.3 --- Marker enzyme measurement (ALT) --- p.83 / Chapter 5.2.3 --- Statistical analysis --- p.83 / Chapter 5.3 --- Results --- p.84 / Chapter 5.3.1 --- Dose-dependent effect of WZ-e on menadione hepatotoxicity --- p.84 / Chapter 5.3.2 --- Dose-dependent effect of WZ-e on menadione hepatotoxicity as illustrated by histopathological observations --- p.86 / Chapter 5.3.3 --- Analyzing he effect of WZ-e and its simplified formulae on menadione-induced hepatotoxicity by Orthogonal Analysis89 --- p.89 / Chapter 5.4 --- Discussion --- p.91 / Conclusion --- p.93 / References --- p.95

Li Qian. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2003. / Includes bibliographical references (leaves 102-117). / Abstracts in English and Chinese. / Abstract --- p.i / Acknowledgements --- p.vi / List of Abbreviations --- p.ix / List of tables and figures --- p.ix / Content --- p.x / Chapter Chapter 1: --- Introduction --- p.1 / Chapter 1.1 --- Traditional Chinese Medicine: Agrimony --- p.1 / Chapter 1.2 --- Hepatocellular carcinoma (HCC) and its risk factors --- p.4 / Chapter 1.3 --- Basic concepts relevant to cancer prevention --- p.6 / Chapter 1.3.1 --- Multistage process of carcinogenesis --- p.6 / Chapter 1.3.2 --- Chemical carcinogenesis --- p.7 / Chapter 1.3.3 --- Possible chemopreventive strategies --- p.8 / Chapter 1.3.4 --- Phase I and phase II systems in chemical carcinogenesis --- p.10 / Chapter Chapter 2 --- Materials and methods --- p.12 / Chapter 2.1 --- Preparation of aqueous extract of Agrimonia pilosa --- p.12 / Chapter 2.2 --- In vivo study --- p.13 / Chapter 2.2.1 --- Animal model for hepatocarcinogenesis --- p.13 / Chapter 2.2.1.1 --- Chemical carcinogens --- p.13 / Chapter 2.2.1.2 --- Animals --- p.16 / Chapter 2.2.1.3 --- Animal treatment and sacrifice --- p.17 / Chapter 2.2.2 --- Histological and immunohistochemical study --- p.20 / Chapter 2.2.3 --- Preparation of liver homogenates and microsomes from rat --- p.23 / Chapter 2.2.4 --- Determination of protein concentration --- p.24 / Chapter 2.2.5 --- COX-2 Activity Assay --- p.25 / Chapter 2.2.6 --- Cytochrome P450 2E1 Assay --- p.26 / Chapter 2.2.7 --- Spectrophotometry Assay for GST --- p.28 / Chapter 2.2.8 --- Isolation of total RNA from liver homogenate --- p.29 / Chapter 2.2.9 --- Semi-quantitative RT-PCR analysis --- p.32 / Chapter 2.3 --- In vitro study --- p.36 / Chapter 2.3.1 --- Cell cultures --- p.36 / Chapter 2.3.2 --- Cytotoxicity assay - Neutral Red Assay --- p.38 / Chapter 2.3.3 --- Cell cycle distribution analysis by flow cytometry --- p.39 / Chapter 2.3.4 --- DNA fragmentation --- p.40 / Chapter Chapter 3 --- Results --- p.43 / Chapter 3.1 --- In vivo study --- p.43 / Chapter 3.1.1 --- Body weight and relative liver weight --- p.43 / Chapter 3.1.2 --- Gross Morphological changes --- p.46 / Chapter 3.1.3 --- Hematoxylin & Eosin (H&E) staining for histological detection --- p.50 / Chapter 3.1.4 --- Effect of AP on DEN-CCl4-induced GST-P positive foci formation and GST-P mRNA expression --- p.60 / Chapter 3.1.5 --- Effects of AP on COX-2 --- p.72 / Chapter 3.1.6 --- Effects of AP on phase I and phase II enzymes --- p.76 / Chapter 3.2 --- In vitro study --- p.80 / Chapter 3.2.1 --- Effects of AP on proliferation of H4IIE cells detected by Neutral Red Assay --- p.80 / Chapter 3.2.2 --- Assessment of cell cycle distribution by flow cytometry --- p.82 / Chapter 3.2.3 --- DNA Fragmentation Assay --- p.88 / Chapter Chapter 4 --- Discussion --- p.90 / Chapter 4.1 --- In vivo study --- p.90 / Chapter 4.1.1 --- Morphological changes during the induction of hepatocarcinogenesis --- p.90 / Chapter 4.1.2 --- Effects of AP on GST-P foci and its mRNA --- p.91 / Chapter 4.1.3 --- Effects of AP on COX-2 enzyme activity and mRNA expression --- p.93 / Chapter 4.1.4 --- Modulation effects of AP on CYP2E1 and GST enzyme activity --- p.95 / Chapter 4.2 --- In vitro study: effects of AP on cancer cell proliferation --- p.97 / Chapter 4.3 --- Summary --- p.99 / References --- p.102

Conclusions. SBL showed its efficacy in treating the animal model of allergic rhinitis. Its mechanisms may be related to its suppressive action on PCA reaction, the production of TXB2 and the expression of eNOS, as well as its modulation of cytokines, including IL-4, IL-6, IL-8, GM-CSF and TNF-alpha, release from mast cells. The clinical trial showed that SBL had more beneficial action on the quality of life, in comparison to the placebo, in the domains of RE and BP. Some symptoms evaluations of PAR patients, including GF, NB and SF were more markedly improved in the SBL group when compared with the placebo group. Furthermore, the use of SBL, with the study dose and treatment period, was safe. However, the accurate efficacy and mechanisms of SBL are largely unknown and need further investigation. (Abstract shortened by UMI.) / Introduction. Although great progress in treatment of allergic rhinitis have made in recent years, remarkably increasing prevalence and cost in epidemiology studies strongly suggest the difficulties in the management of allergic rhinitis. Shi-Bi-Lin (SBL) is a formula modified from the traditional Chinese herbal formula Cang-Er-Zi-San (CEZS) and a classic European formula SinupretRTM. CEZS has been used for the treatment of allergic rhinitis for several centuries in East Asia communities, and SinupretRTM has been used in treating paranasal sinusitis and rhinitis widely in Europe for decades. However, its therapeutic mechanisms remain unclear. We examined the efficacy and the possible mechanism of SBL in an animal model of allergic rhinitis and in cell culture study using Human Mast Cell Line (HMC-1) and Peripheral Blood Mononuclear Cells (PBMC). In addition, a clinical trial was conducted to examine its clinical efficacy and safety. / Results. In the animal study, SBL showed a potent effect in relieving the symptoms of nasal obstruction, sneezing and nasal scratching (P<0.05 or P<0.01), but had no convincing effect in decreasing the nasal discharge (P>0.05). In PCA test, IgG1 increased in a modest manner in the SBL-treated group when compared with the sham group (P<0.05 or P<0.01). Eosinophil infiltration and the expression of eNOS in nasal mucosa, but not iNOS, were obviously lower in the SBL treated group (P<0.05 or P<0.01) in comparison to the sham group. The levels of thromboxane B (TXB)2 in the nasal lavage fluid, but not histamine and peptide leukotrienes (p-LTs), showed significantly lower than that of the sham group (P<0.05). In vitro study showed that SBL modulated the cytokines, including interleukin (IL)-4, IL-6, IL-8, Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) and tumor necrosis factor (TNF)-alpha, release from human mast cell line (HMC-1). However, the mRNA expressions of these cytokines were not significantly altered. As the controls, dexamethasone, desloratadine and budesonide had more potently inhibitory effects on cytokines release from HMC-1. The component herbs generally had stimulatory effects on the cytokine release from HMC-1 and variable effects on PBMC. In the clinical trial, a total of 84 patients were recruited in the clinical trial and 77 of them completed the trial. Although no significant differences of each domain between the SBL and placebo groups were detected, findings supported the efficacy of SBL were obtained. / by Zhao Yu. / "July 2005." / Advisers: C. A. Van Hasselt; Ping-Chung Leung; Kong-Sang Woo. / Source: Dissertation Abstracts International, Volume: 67-01, Section: B, page: 0172. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references. / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract in English and Chinese. / School code: 1307.

Song Jingzheng. / "June 2004." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (p. 170-186). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

by Jing Xian Li. / Thesis (Ph.D.)--Chinese university of Hong Kong, 1998. / Includes bibliographical references (p. 137-151). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

Wong, Ngan Yuk. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2010. / Includes bibliographical references (leaves 114-128). / Abstracts in English and Chinese. / Thesis/Assessment Committee --- p.i / Declaration --- p.ii / Abstract (in English) --- p.iii / Abstract (in Chinese) --- p.v / Acknowledgments --- p.vi / Table of Contents --- p.vii / List of Abbreviations --- p.xi / List of Figures --- p.xiv / List of Tables --- p.xvi / Chapter 1. --- Literature review --- p.1 / Chapter 1.1. --- Introduction to Cordyceps --- p.1 / Chapter 1.2. --- Ingredients of Cordyceps and their related biological activities --- p.4 / Chapter 1.2.1. --- "Amino acids, peptides, proteins and polyamines" --- p.4 / Chapter 1.2.1.1. --- Proteins --- p.4 / Chapter 1.2.2. --- Saccharides and sugar derivatives --- p.7 / Chapter 1.2.2.1. --- Polysaccharides --- p.7 / Chapter 1.2.3. --- Nucleosides --- p.9 / Chapter 1.2.3.1. --- Cordycepin --- p.9 / Chapter 1.2.3.2. --- Adenosine --- p.12 / Chapter 1.2.4. --- Fatty acids and sterols --- p.14 / Chapter 1.2.5. --- Vitamins and inorganics --- p.15 / Chapter 1.3. --- Cordyceps and their related biological activities --- p.15 / Chapter 1.3.1. --- Cordyceps militaris --- p.15 / Chapter 1.3.2. --- Cordyceps sinensis --- p.17 / Chapter 1.4. --- Proteomic tools used to study the change in protein expression profiles --- p.21 / Chapter 1.4.1. --- Proteomic tools in studies of the change in protein expression --- p.21 / Chapter 1.4.2. --- Two-dimensional gel electrophoresis --- p.22 / Chapter 1.4.3. --- Mass spectrometry --- p.22 / Chapter 1.4.4. --- Current challenges --- p.23 / Chapter 2. --- Methodology --- p.25 / Chapter 2.1. --- Cultivation of Cordyceps militaris --- p.25 / Chapter 2.2. --- Preparation of Cordyceps extracts for anti-proliferation assay on cell lines --- p.26 / Chapter 2.2.1. --- Types of the extracts of Cordyceps --- p.26 / Chapter 2.2.2. --- Preparation of the Cordyceps extracts --- p.26 / Chapter 2.3. --- Anti-proliferation assay on cell lines for extract screening --- p.26 / Chapter 2.3.1. --- Cell lines and culturing condition --- p.26 / Chapter 2.3.2. --- Viable cell count using trypan blue exclusion method --- p.27 / Chapter 2.3.3. --- Anti-proliferation assay on cell lines using MTT assay --- p.28 / Chapter 2.3.4. --- Determination of the IC50 values --- p.30 / Chapter 2.3.5. --- Statistical Analysis --- p.30 / Chapter 2.4. --- Proteomic studies for HepG2 and Hs68 after the treatment of extracts --- p.30 / Chapter 2.4.1. --- Protein sample preparation of HepG2and Hs68 --- p.30 / Chapter 2.4.2. --- Protein quantitation --- p.31 / Chapter 2.4.3. --- 2D Gel electrophoresis --- p.33 / Chapter 2.4.4. --- Image analysis --- p.34 / Chapter 2.4.5. --- In gel digestion and MALDI-ToF MS --- p.35 / Chapter 2.5. --- Cell cycle analysis --- p.36 / Chapter 2.5.1. --- Cell samples preparation --- p.36 / Chapter 2.5.2. --- Popidium iodide staining --- p.36 / Chapter 2.5.3. --- Flow cytometry --- p.37 / Chapter 2.5.4. --- Statistical Analysis --- p.38 / Chapter 2.6. --- Western blotting --- p.38 / Chapter 2.6.1. --- Protein sample preparation of HepG2 and Hs68 --- p.38 / Chapter 2.6.2. --- SDS-PAGE --- p.38 / Chapter 2.6.3. --- Protein Transblotting --- p.39 / Chapter 2.6.4. --- Membrane Blocking and Antibody Incubations --- p.39 / Chapter 2.6.5. --- Detection of Proteins --- p.40 / Chapter 3. --- Results --- p.41 / Chapter 3.1. --- Investigation of anti-proliferating effect of Cordyceps extracts on HepG2 and Hs68 using MTT assays --- p.41 / Chapter 3.1.1. --- Cordyceps militaris fruiting body extract - CMFB --- p.41 / Chapter 3.1.2. --- Cordyceps militaris mycelia extract - CMM --- p.41 / Chapter 3.1.3. --- Cordyceps sinensis fruiting body extract - CSFB --- p.45 / Chapter 3.1.4. --- Cordyceps sinensis mycelia extract - CSM --- p.45 / Chapter 3.1.5. --- "Comparison of the anti-proliferation effects of the Cordyceps extracts CMFB, CMM, CSFB and CSM" --- p.49 / Chapter 3.2. --- "Investigation of anti-proliferating effect of Cordyceps militaris extracts on H292, Neuro2a and WIL2-NS using MTT assays" --- p.51 / Chapter 3.2.1. --- Cordyceps militaris fruiting body extract - CMFB --- p.51 / Chapter 3.2.2. --- Cordyceps militaris mycelia extract - CMM --- p.51 / Chapter 3.3. --- Changes in total protein expression profiles in cell lines --- p.56 / Chapter 3.3.1. --- Protein samples preparation --- p.56 / Chapter 3.3.2. --- 2D gel electrophoresis analysis of protein from cell lines --- p.56 / Chapter 3.3.2.1. --- HepG2 --- p.57 / Chapter 3.3.2.2. --- Hs68 --- p.58 / Chapter 3.3.3. --- Differentially expressed proteins identification --- p.66 / Chapter 3.3.3.1. --- HepG2 --- p.66 / Chapter 3.3.3.2. --- Hs68 --- p.67 / Chapter 3.4. --- Cell cycle analysis --- p.76 / Chapter 3.4.1. --- Cell samples preparation --- p.76 / Chapter 3.4.2. --- HepG2 --- p.76 / Chapter 3.4.3. --- Hs68 --- p.77 / Chapter 3.4.4. --- H292 --- p.77 / Chapter 3.5. --- Western blotting --- p.81 / Chapter 3.5.1. --- Protein samples preparation --- p.81 / Chapter 3.5.2. --- Detection of actin for protein loading normalization --- p.83 / Chapter 3.5.3. --- Detection of procaspase-3 and cleaved caspase-3 --- p.83 / Chapter 3.5.4. --- Detection of procaspase-7 and cleaved caspase-7 --- p.84 / Chapter 3.5.5. --- Detection of procaspase-9 and cleaved caspase-9 --- p.84 / Chapter 4. --- Discussion --- p.86 / Chapter 4.1. --- Anti-tumor proliferating effect of Cordyceps extracts --- p.86 / Chapter 4.2. --- Changes in total protein expression profiles in cell lines --- p.87 / Chapter 4.2.1. --- Differentially expressed proteins in HepG2 treated with fruiting body extract --- p.88 / Chapter 4.2.1.1. --- Heat shock 90kDa protein 1 beta (HSP90(β) --- p.89 / Chapter 4.2.1.2. --- Far upstream element-binding protein 1 (FUBP-1) --- p.90 / Chapter 4.2.1.3. --- RuvB-like 1 (RuvbLl) --- p.90 / Chapter 4.2.1.4. --- Acidic protein rich in leucine (APRIL) --- p.91 / Chapter 4.2.1.5. --- SET protein --- p.92 / Chapter 4.2.1.6. --- Enolase 1 (α-enolase) --- p.94 / Chapter 4.2.1.7. --- Aldolase A --- p.96 / Chapter 4.2.1.8. --- DNA-binding protein B --- p.96 / Chapter 4.2.1.9. --- Peroxiredoxin 1 (Prx 1) --- p.97 / Chapter 4.2.1.10. --- Proteasome activator subunit 1 iso form 1 --- p.99 / Chapter 4.2.1.11. --- Dehydrogenase/ reductase member 2 isoform 2 --- p.99 / Chapter 4.2.1.12. --- Protein disulfide isomerase- related protein 5 --- p.100 / Chapter 4.2.1.13. --- Annexin IV --- p.100 / Chapter 4.2.1.14. --- Enoyl Coenzyme A hydratase --- p.101 / Chapter 4.2.2. --- Differentially expressed proteins in HepG2 treated with mycelia extract --- p.102 / Chapter 4.2.2.1. --- Alpha actinin 4 --- p.102 / Chapter 4.2.2.2. --- SET translocation isoform 1 --- p.103 / Chapter 4.2.2.3. --- Acidic (leucine-rich) nuclear phosphoprotein 32 family member B (ANP32b) --- p.103 / Chapter 4.2.2.4. --- Endoplasmic reticulum protein 29 isoform 1 precursor (ERp29) --- p.103 / Chapter 4.2.2.5. --- Heterogeneous nuclear ribonucleoprotein H3 isoform b (hnRNP 2H9A) --- p.104 / Chapter 4.2.3. --- Differentially expressed proteins in Hs68 treated with fruiting body extract --- p.105 / Chapter 4.2.3.1. --- Lamin A/C isoform 2 --- p.105 / Chapter 4.2.3.2. --- Vimentin --- p.106 / Chapter 4.2.3.3. --- Tropomyosin 1 alpha chain isoform 4 --- p.107 / Chapter 4.2.3.4. --- Rho GDP dissociation inhibitor (GDI) alpha (RhoGDIα) --- p.109 / Chapter 4.2.3.5. --- Dihydropyrimidinase-like 2 (DRP-2) --- p.109 / Chapter 4.2.3.6. --- Keratin 7 (K7) --- p.110 / Chapter 4.2.4. --- Differentially expressed proteins in Hs68 treated with mycelia extract --- p.111 / Chapter 4.3. --- Cell cycle analysis --- p.111 / Chapter 4.4. --- Western blotting --- p.113 / Chapter 5. --- References --- p.114

Chan, Chun Kit. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2008. / Includes bibliographical references (leaves 147-161). / Abstracts in English and Chinese. / Chapter Chaper 1 --- Introduction --- p.1 / Chapter 1.1 --- General introduction to cerebral stroke --- p.1 / Chapter 1.2 --- Different types of cerebral stroke --- p.2 / Chapter 1.3 --- Statistics --- p.3 / Chapter 1.4 --- Symptoms of cerebral stroke --- p.4 / Chapter 1.5 --- Complications of cerebral stroke --- p.5 / Chapter 1.6 --- Risks and preventions of cerebral stroke --- p.6 / Chapter 1.7 --- Cerebral stroke treatment --- p.8 / Chapter 1.8 --- Post stroke rehabilitation --- p.11 / Chapter 1.9 --- Mechanisms of stroke --- p.15 / Chapter 1.9.1 --- Energy production failure and loss of ionic homeostasis --- p.15 / Chapter 1.9.2 --- Excitotoxicity --- p.16 / Chapter 1.9.3 --- Calcium ions mediated toxicity --- p.17 / Chapter 1.9.4 --- Passive neuronal cell death --- p.18 / Chapter 1.9.5 --- Oxidative stress --- p.19 / Chapter 1.9.6 --- Inflammation --- p.22 / Chapter 1.9.7 --- Apoptosis --- p.25 / Chapter 1.10 --- Potential therapeutic agents for cerebral stroke --- p.24 / Chapter 1.10.1 --- Anti-oxidative enzyme and free radical scavengers --- p.24 / Chapter 1.10.2 --- Ions channel blockers and glutamate antagonists --- p.26 / Chapter 1.10.3 --- Anti-inflammatory agent --- p.28 / Chapter 1.10.4 --- Anti-apoptotic agent --- p.28 / Chapter 1.11 --- Experimental model of cerebral ischemia-reperfusion --- p.29 / Chapter 1.11.1 --- In vitro model (oxygen and glucose deprivation model) --- p.29 / Chapter 1.11.2 --- In vivo model (Middle cerebral artery occlusion) --- p.31 / Chapter 1.12 --- Traditional Chinese Medicine (TCM) --- p.32 / Chapter 1.12.1 --- General Introduction to Traditional Chinese Medicine --- p.32 / Chapter 1.12.2 --- TCM and cerebral stroke --- p.33 / Chapter 1.12.3 --- Chinese compound formula --- p.34 / Chapter 1.12.4 --- Introduction to individual herb --- p.34 / Chapter 1.12.4.1 --- Astragali Radix (Pinyin name: Huangqi) --- p.34 / Chapter 1.12.4.2 --- Rhizoma Chuanxiong (Pinyin name: Chuanxiong) --- p.35 / Chapter 1.12.4.3 --- Radix Salviae Miltorrhizae (Pinyin name: Danshen) --- p.35 / Chapter 1.12.4.4 --- Cassia Obtusifolia Linne (Pinyin name: Jue Ming Zi) --- p.36 / Chapter 1.12.4.5 --- Radix Glycyrrhizae (Pinyin name: Gancao) --- p.37 / Chapter 1.12.4.6 --- Radix Angelicae Sinensis (Pinyin name: Dongquai) --- p.37 / Chapter 1.12.4.7 --- Paeoniae Veitchii Radix (Pinyin name: Chi Shao) --- p.38 / Chapter 1.12.5 --- Salvianolic acid B --- p.39 / Chapter 1.13 --- Aim of study --- p.40 / Chapter Chapter 2 --- Materials and Methods --- p.41 / Chapter 2.1 --- Materials --- p.41 / Chapter 2.1.1 --- Drug --- p.41 / Chapter 2.1.1.1 --- Herbal Medicine --- p.41 / Chapter 2.1.1.2 --- Herbal extraction of PSR --- p.42 / Chapter 2.1.1.3 --- Herbal extraction of individual herb --- p.43 / Chapter 2.1.1.4 --- Salvianolic acid B --- p.43 / Chapter 2.1.2 --- Chemical --- p.44 / Chapter 2.1.3 --- Animal --- p.48 / Chapter 2.2 --- Methods --- p.49 / Chapter 2.2.1 --- (AAPH)- induced erythrocyte hemolysis --- p.49 / Chapter 2.2.2 --- Cell Culture study --- p.51 / Chapter 2.2.2.1 --- Cell Line --- p.51 / Chapter 2.2.2.2 --- Cell differentiation --- p.52 / Chapter 2.2.2.3 --- In vitro model of ischemia - Oxygen glucose deprivation (OGD) experiment --- p.53 / Chapter 2.2.2.4 --- Cell viability assay --- p.54 / Chapter 2.2.3 --- In vivo Study --- p.54 / Chapter 2.2.3.1 --- Cerebral blood flow (CBF) measurement --- p.54 / Chapter 2.2.3.2 --- In vivo transient focal cerebral ischemia model - Middle cerebral artery occlusion (MCAo) --- p.55 / Chapter 2.2.3.3 --- Administration of PSR --- p.57 / Chapter 2.2.3.4 --- Administration of salvianolic acid B (SAB) --- p.59 / Chapter 2.2.3.5 --- Measurement of brain infarct volume --- p.60 / Chapter 2.2.3.6 --- In vivo anti-oxidative enzyme activity determination in the brain --- p.61 / Chapter 2.2.3.6.1 --- Brain tissue preparation --- p.61 / Chapter 2.2.3.6.2 --- Tissue homogenization and protein extraction --- p.61 / Chapter 2.2.3.6.3 --- Protein concentration determination --- p.63 / Chapter 2.2.3.6.4 --- Catalase activity determination in the brain --- p.63 / Chapter 2.2.3.6.5 --- Glutathione Peroxidase (GPx) activity determination in the brain --- p.64 / Chapter 2.2.3.6.6 --- The Superoxide Dismutase (SOD) activity determination in the brain --- p.65 / Chapter 2.2.3.7 --- Behavioral Evaluation --- p.66 / Chapter 2.2.3.7.1 --- Neurological behavioural test --- p.66 / Chapter 2.2.3.7.2 --- Shuttle box escape experiment --- p.67 / Chapter 2.3 --- Statistical analyses --- p.71 / Chapter Chapter 3 --- Results --- p.72 / Chapter 3.1 --- In vitro model of ischemia - Oxygen glucose and deprivation (OGD) experiment --- p.72 / Chapter 3.2 --- AAPH assay of PSR --- p.75 / Chapter 3.3 --- AAPH assay of individual herb --- p.77 / Chapter 3.4 --- Brain slices after middle cerebral artery occlusion (MCAo) experiment --- p.81 / Chapter 3.5 --- Brain infarct volume of single dose protocol --- p.83 / Chapter 3.6 --- Neurological behavioural test of single dose protocol --- p.85 / Chapter 3.7 --- Brain infarct volume of double doses protocol --- p.87 / Chapter 3.8 --- Neurological behavioural test of double doses protocol --- p.89 / Chapter 3.9 --- Determination of superoxide dismutase (SOD) activity in the brain --- p.91 / Chapter 3.10 --- Determination of glutathione peroxidase (GPx) activity in the brain --- p.93 / Chapter 3.11 --- Determination of catalase activity in the brain --- p.95 / Chapter 3.12 --- Brain infarction volume of Salvianolic acid B (SAB) treatment --- p.98 / Chapter 3.13 --- Neurological behavioural test of SAB treatment --- p.100 / Chapter 3.14 --- Shuttle box performance in training and testing series --- p.102 / Chapter 3.15 --- Change in shuttle box performance (% avoidance c.f. last day of training) in testing series --- p.104 / Chapter 3.16 --- Escape latency in testing and training series --- p.107 / Chapter 3.17 --- Change in escape latency (c.f. last day of training) in testing series --- p.109 / Chapter 3.18 --- Brain infarct volume of shuttle box escape experiment --- p.112 / Chapter 3.19 --- Neurological score in shuttle box escape experiment --- p.114 / Chapter Chapter 4 --- Discussion --- p.117 / Chapter 4.1 --- The protective effect of PSR in in vitro oxygen and glucose deprivation (OGD) on human neuroblastoma SH-SY5Y cell line --- p.117 / Chapter 4.1.1 --- OGD model and cell line --- p.117 / Chapter 4.1.2 --- Protective effect of PSR in OGD experiment --- p.118 / Chapter 4.1.3 --- Free radical scavenging property of PSR --- p.120 / Chapter 4.2 --- The protective effects of PSR in in vivo middle cerebral artery (MCAo) model --- p.121 / Chapter 4.2.1 --- The shortcomings of in vitro OGD model --- p.121 / Chapter 4.2.2 --- Development of in vivo MCAo model and TTC staining --- p.122 / Chapter 4.2.3 --- Protective effect of PSR in MCAo experiment (single dose protocol) --- p.124 / Chapter 4.2.4 --- Protective effect of PSR in MCAo experiment (double doses protocol) --- p.125 / Chapter 4.2.5 --- The effect of PSR toward neurological deficits --- p.127 / Chapter 4.2.6 --- Anti-oxidative effects of PSR in MCAo model --- p.128 / Chapter 4.3 --- The protective effects of SAB in in vivo middle cerebral artery (MCAo) model --- p.130 / Chapter 4.3.1 --- Free radical scavenging property of different herbs --- p.130 / Chapter 4.3.2 --- Selection of pure compound that used to treat stroke --- p.131 / Chapter 4.3.3 --- Protective effect of Salvianolic B in MCAo experiment --- p.132 / Chapter 4.3.4 --- The effect of SAB toward neurological deficits --- p.133 / Chapter 4.4 --- The effects of PSR and SAB on stroked rats' performance in shuttle box escape experiment --- p.134 / Chapter 4.4.1 --- Establishment of shuttle box escape experiment --- p.134 / Chapter 4.4.2 --- Effects of PSR and SAB on avoidance performance --- p.135 / Chapter 4.4.3 --- Effects of PSR and SAB on escape latency --- p.138 / Chapter 4.5 --- Assessment on the contribution of SAB to the protective effect of PSR --- p.140 / Chapter 4.6 --- Comparison of acute and chronic testing --- p.140 / Chapter 4.6.1 --- The protective effect of the drugs (Histopathological examination) --- p.140 / Chapter 4.6.2 --- The severity of motor deficit (Neurological score) --- p.141 / Chapter Chapter 5 --- Conclusion and Future prospect --- p.143 / Chapter 5.1 --- Conclusion --- p.143 / Chapter 5.2 --- Future prospect --- p.144 / References --- p.147

Chan, Hoi Ling. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2008. / Includes bibliographical references (leaves 206-220). / Abstracts in English and Chinese. / ACKNOWLEDGEMENTS --- p.i / ABBREVIATIONS --- p.ii / ABSTRACT --- p.viii / 撮要 --- p.xii / PUBLICATIONS --- p.xiv / TABLE OF CONTENTS --- p.xv / Chapter CHAPTER 1: --- GENERAL INTRODUCTION / Chapter 1.1 --- Hematopoiesis & Leukemia --- p.1 / Chapter 1.1.1 --- An Overview on Hematopoiesis Development --- p.1 / Chapter 1.1.2 --- Leukemia --- p.6 / Chapter 1.1.2.1 --- General Symptoms of Leukemia --- p.7 / Chapter 1.1.2.2 --- Classification of Leukemia --- p.8 / Chapter 1.1.2.3 --- Conventional Treatment against Leukemia --- p.15 / Chapter 1.1.2.4 --- Novel Approaches --- p.19 / Chapter 1.2 --- The Chinese Medicinal Herb-Banlangen (板藍根） --- p.24 / Chapter 1.2.1 --- An Overview on Natural Indigo Compounds Derived from Banlangen --- p.24 / Chapter 1.2.2 --- Tryptanthrin --- p.29 / Chapter 1.2.2.1 --- Anti-bacterial Activity of Tryptanthrin --- p.29 / Chapter 1.2.2.2 --- Anti-tumor Activity of Tryptanthrin --- p.31 / Chapter 1.2.2.3 --- Anti-inflammatory Activity of Tryptanthrin --- p.33 / Chapter 1.2.2.4 --- Cutting Edges of Tryptanthrin as a Drug --- p.34 / Chapter 1.2.2.5 --- Metabolism of Tryptanthrin --- p.35 / Chapter 1.3 --- Aims and Scopes of This Investigation --- p.37 / Chapter CHAPTER 2: --- MATERIALS AND METHODS / Chapter 2.1 --- Materials --- p.39 / Chapter 2.1.1 --- Animals --- p.39 / Chapter 2.1.2 --- Cell Lines --- p.39 / Chapter 2.1.3 --- "Cell Culture Medium, Buffers and Other Reagents" --- p.41 / Chapter 2.1.4 --- Reagents for 3H-Thymidine Incorporation Assay --- p.45 / Chapter 2.1.5 --- Reagents and Buffers for Flow Cytometry --- p.46 / Chapter 2.1.6 --- Reagents for DNA Extraction --- p.49 / Chapter 2.1.7 --- Reagents for Measuring Caspase Activity --- p.50 / Chapter 2.1.8 --- Reagents for Total RNA Isolation --- p.53 / Chapter 2.1.9 --- Reagents and Buffers for Reversed Transcription-PCR --- p.54 / Chapter 2.1.10 --- Reagents and Buffers for Real Time-PCR --- p.59 / Chapter 2.1.11 --- Reagents and Buffers for Gel Electrophoresis of Nucleic Acids --- p.59 / Chapter 2.1.12 --- "Reagents, Buffers and Materials for Western Blot Analysis" --- p.61 / Chapter 2.2 --- Methods --- p.70 / Chapter 2.2.1 --- Culture of the Tumor Cell Lines --- p.70 / Chapter 2.2.2 --- "Isolation, Preparation and Culture of Mouse Peritoneal Macrophages" --- p.70 / Chapter 2.2.3 --- Determination of Cell Viability --- p.71 / Chapter 2.2.4 --- Determination of Cell Proliferation by [3H]-TdR Incorporation Assay --- p.72 / Chapter 2.2.5 --- Determination of Anti-leukemia Activity In Vivo --- p.73 / Chapter 2.2.6 --- Analysis of Cell Cycle Profile/DNA Content by Flow Cytometry --- p.74 / Chapter 2.2.7 --- Measurement of Apoptosis --- p.75 / Chapter 2.2.8 --- Determination of the Mitochondrial Membrane Potential --- p.77 / Chapter 2.2.9 --- Measurement of Caspase Activity --- p.78 / Chapter 2.2.10 --- Study of Intracellular Accumulation of Reactive Oxygen Species --- p.79 / Chapter 2.2.11 --- Gene Expression Study --- p.80 / Chapter 2.2.12 --- Protein Expression Study --- p.83 / Chapter 2.2.13 --- Measurement of Cell Differentiation --- p.87 / Chapter CHAPTER 3: --- STUDIES ON THE ANTI-PROLIFERATIVE EFFECT OF TRYPTANTHRIN AND INDIRUBIN-3'-OXIME ON MYELOID LEUKEMIA CELLS / Chapter 3.1 --- Introduction --- p.90 / Chapter 3.2 --- Results --- p.94 / Chapter 3.2.1 --- Effects of Indirubin-3'-oxime and Tryptanthrin on the Proliferation of Myeloid Leukemia Cell Lines of Human and Murine Origins In Vitro --- p.94 / Chapter 3.2.2 --- Kinetic and Reversibility Studies of the Anti-proliferative Effect of Tryptanthrin on Murine Myelomonocytic Leukemia WEHI-3B JCS Cells In Vitro --- p.108 / Chapter 3.2.3 --- Cytotoxic Effect of Tryptanthrin on Murine Myelomonocytic Leukemia WEHI-3B JCS Cells In Vitro --- p.113 / Chapter 3.2.4 --- Cytotoxicity of Tryptanthrin on Non-Cancer Cell Line and Primary Myeloid Cells In Vitro --- p.115 / Chapter 3.2.5 --- Effects of Tryptanthrin on the Cell Cycle Profile of the Murine Myelomonocytic Leukemia WEHI-3B JCS Cells In Vitro --- p.118 / Chapter 3.2.6 --- Effects of Tryptanthrin on the Expression of Cell Cycle Related Genes in Murine Myelomonocytic Leukemia WEHI-3B JCS Cells In Vitro --- p.123 / Chapter 3.2.7 --- Expression of CDK-inhibitors in Tryptanthrin-treated Murine Myeloid Leukemia WEHI-3B JCS Cells --- p.126 / Chapter 3.2.8 --- Effects of Tryptanthrin on the In Vivo Tumorigenicity of the Murine Myelomonocytic Leukemia WEHI-3B JCS Cells --- p.128 / Chapter 3.2.9 --- In Vivo Anti-tumor Effect of Tryptanthrin on Murine Myelomonocytic Leukemia WEHI-3B JCS Cells --- p.130 / Chapter 3.3 --- Discussion --- p.132 / Chapter CHAPTER 4: --- STUDIES ON THE APOPTOSIS-INDUCING EFFECT OF TRYPTANTHRIN ON MURINE MYELOMONOCYTIC LEUKEMIA WEHI-3B JCS CELLS / Chapter 4.1 --- Introduction --- p.139 / Chapter 4.2 --- Results --- p.143 / Chapter 4.2.1 --- Induction of DNA Fragmentation by Tryptanthrin in the Murine Myelomonocytic Leukemia WEHI-3B Cells In Vitro --- p.143 / Chapter 4.2.2 --- Induction of Phosphatidylserine Externalization by Tryptanthrin in Murine Myelomonocytic Leukemia WEHI-3B JCS Cells --- p.145 / Chapter 4.2.3 --- Change of Mitochondrial Membrane Potential of Tryptanthrin- treated Murine Myelomonocytic Leukemia WEHI-3B JCS Cells --- p.147 / Chapter 4.2.4 --- Induction of Caspase Activity in Tryptanthrin-treated Murine Myelomonocytic Leukemia WEHI-3B JCS cells --- p.150 / Chapter 4.2.5 --- Induction of Reactive Oxygen Species in Tryptanthrin-treated Murine Myelomonocytic Leukemia WEHI-3B JCS cells --- p.155 / Chapter 4.2.6 --- Expression of Bcl-2 Family Proteins in the Tryptanthrin-treated Murine Myelomonocytic Leukemia WEHI-3B JCS cells --- p.160 / Chapter 4.2.7 --- Effects of Tryptanthrin on the mRNA Expression of Bcl-2 Family Proteins in Murine Myelomonocytic Leukemia WEHI-3B JCS Cells --- p.163 / Chapter 4.2.8 --- Expression of Fas and Fas Ligand Proteins in Tryptanthrin-treated Murine Myelomonocytic Leukemia WEHI-3B JCS cells --- p.167 / Chapter 4.2.9 --- Expression of Pro-Apoptotic Protein in Tryptanthrin- treated Murine Myelomonocytic Leukemia WEHI-3B JCS cells --- p.170 / Chapter 4.2 --- Discussion --- p.173 / Chapter CHAPTER 5: --- STUDIES ON THE DIFFERENTIATION-INDUCING ABILITY OF TRYPTANTHRIN ON MURINE MYELOMONOCYTIC LEUKEMIA WEHI-3B JCS CELLS / Chapter 5.1 --- Introduction --- p.184 / Chapter 5.2 --- Results --- p.186 / Chapter 5.2.1 --- Morphological Studies on Tryptanthrin-treated Murine Myelomonocytic Leukemia WEHI-3B JCS Cells --- p.186 / Chapter 5.2.2 --- Effects of Tryptanthrin on the Cell Size and Granularity of the Murine Myelomonocytic Leukemia WEHI-3B JCS Cells --- p.189 / Chapter 5.2.3 --- Effects of Tryptanthrin on Induction of NBT-reducing Activity in the Murine Myelomonocytic Leukemia WEHI-3B JCS Cells --- p.191 / Chapter 5.3 --- Discussion --- p.195 / Chapter CHAPTER 6: --- CONCLUSIONS AND FUTURE PERSPECTIVES --- p.198 / REFERENCES --- p.206